FDA approves XNPT Horizant. OREX initiates cardio outcomes trial. AIS to transfer to NASDAQ. ACHN CMO resigns + NBY news
GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced the FDA approved their supplemental new drug application of Horizant for the management of postherpetic neuralgia (PHN) in adults.
Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that it has initiated its cardiovascular outcomes trial, called the Light-Study, evaluating the occurrence of major adverse cardiovascular events (MACE) in patients taking Contrave, for the treatment of obesity. An interim analysis and NDA submission is planned once 87 MACE events have occurred, which is expected to be by mid-2014.
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced the resignation of Elizabeth A. Olek, D.O., Senior Vice President of Clinical Development and Chief Medical Officer, effective June 18, 2012.
NovaBay Pharmaceuticals, Inc. (NYSE AMEX: NBY) said that it expects to initiate a global Phase 2b trial of NVC-422 for treating impetigo, during 3Q 2012.
Antares Pharma, Inc. (NYSE Amex: AIS) announced that it will transfer from the NYSE Amex Exchange to the NASDAQ Capital Market on June 15, 2012 under the ticker symbol “ATRS.”